About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
GRACE
cancergrace.org
Podcast Series
Targeted Therapies in Lung Cancer 2023
ASCO® 2023
Lung Cancer OncTalk
Blood Cancer OncTalk
2022 Melanoma Video Library
OncTalk 2022
ASCO Lung Review 2022
ASCO and ESMO Lung Recap
2021 Targeted Therapies Patient Forum
COVID-19
Lung
Hematologic Oncology
Head and Neck
Brain
Palliative
Genitourinary
General
Breast
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
EGFR Initial Treatment and Acquired Resistance in Advanced NSCLC
By
GRACE
FEATURING
Helena Yu
By
GRACE
FEATURING
Helena Yu
170 views
July 22, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
20:59
Exelixis
Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…
Feat.
S. Ratnam
Featured Video
20:00
Exelixis
Child-Pugh Classification and its Role in Treatment Decisions in Pat…
Feat.
P. Gholam
Lung
02:41
GRACE
Staging Disease: How Oncologists Stage NSCLC
Feat.
I. Dagogo-Jack,
M. Das,
C. Jeffery Yang
03:19
GRACE
Biomarkers in NSCLC
Feat.
I. Dagogo-Jack,
M. Das,
C. Jeffery Yang
06:09
GRACE
Perioperative vs. Preoperative Surgery in NSCLC
Feat.
I. Dagogo-Jack,
M. Das,
C. Jeffery Yang
03:25
GRACE
Antibody Drug Conjugates and How They Are Used in NSCLC
Feat.
L. Bazhenova
02:36
GRACE
ADC Treatment in NSCLC
Feat.
L. Bazhenova
03:15
GRACE
Bispecific Antibodies in Lung Cancer
Feat.
L. Bazhenova
02:52
GRACE
Amivantamab in 1L Advanced NSCLC With EGFR exon 20 Insertion Mutatio…
Feat.
L. Bazhenova
05:47
GRACE
Treatment Options for EGFR+ NSCLC
Feat.
I. Dagogo-Jack,
N. Vokes
03:42
GRACE
Surgical Options for Stage IV NSCLC With Brain Metastases: 60 y/o Wo…
Feat.
I. Dagogo-Jack,
J. Reuss
06:02
GRACE
Neoadjuvant Chemo +/- Nivo for Patients With Early Stage NSCLC: Case…
Feat.
I. Dagogo-Jack,
J. Reuss
03:21
GRACE
Treating Stage III NSCLC: Case-Based Panel Discussion
Feat.
I. Dagogo-Jack,
K. Arbour
03:44
GRACE
How Oncologists Stage Disease - Case-Based Panel Discussion: 50 y/o …
Feat.
I. Dagogo-Jack,
J. Reuss,
N. Vokes,
K. Arbour
09:37
GRACE
Is Broad NGS the Standard of Care in Advanced NSCLC?
Feat.
I. Dagogo-Jack,
M. Marmarelis,
A. Sacher,
A. Hegde
05:27
GRACE
Neoadjuvant Therapy vs. Adjuvant Therapy in NSCLC: What Is the Futur…
Feat.
J. West,
E. Rodriguez,
R. Shah,
N. Duma
05:38
GRACE
Surgical vs. Nonsurgical Treatment in Early NSCLC
Feat.
J. West,
E. Rodriguez,
R. Shah,
N. Duma
07:28
CancerGRACE
Early Stage NSCLC: PD-L1 and Durvalumab
Feat.
J. West,
E. Rodriguez,
R. Shah,
N. Duma
04:35
GRACE
Testing in Potentially Resectable & Unresectable Locally Advance…
Feat.
J. West,
E. Rodriguez,
R. Shah,
N. Duma
22:49
CancerGRACE
The Need for Broad Molecular Testing for Driver Mutations in NSCLC
Feat.
J. Gainor
26:08
GRACE
NSCLC Frontline Therapy for Uncommon Mutations: Overview of RET, NTR…
Feat.
J. Gainor
06:15
CancerGRACE
Expert Discussion on Targeted Therapy for mNSCLC: Can ALK Inhibitors…
Feat.
J. West
18:10
GRACE
A Case of a NSCLC KRAS 71 y/o Female With Underlying Autoimmune Cond…
Feat.
S. Liu,
J. Brahmer,
B. Levy
15:42
CancerGRACE
Expert Analysis of 1L EGFR+ Advanced NSCLC Options: 1st Gen Gefitini…
Feat.
J. Weiss
10:33
GRACE
Targeted Therapy for EGFR+ NSCLC: How Do We Think About Acquired Res…
Feat.
Z. Piotrowska
18:15
CancerGRACE
Targeted Therapy for EGFR+ NSCLC: What Are the Current Options Upon …
Feat.
Z. Piotrowska
05:41
GRACE
ASCO Expert Discussion on Malignant Pleural Mesothelioma: Does Durva…
Feat.
J. West,
H. Yu,
D. Spigel
05:47
GRACE
ASCO Roundtable on 2L Malignant Pleural Mesothelioma: How Encouragin…
Feat.
J. West,
H. Yu,
D. Spigel
10:25
CancerGRACE
IO for Unresectable Stage 3 NSCLC: Does Durvalumab Help Patients? Wh…
Feat.
M. Das
08:13
CancerGRACE
2020 ASCO Highlights on RT+ Chemo in LS-SCLC: Is There a Difference …
Feat.
J. West,
H. Yu,
D. Spigel
16:22
GRACE
2020 ASCO ADAURA Trial Update on Adjuvant Osimertinib in EGFR+ NSCLC…
Feat.
H. Yu,
D. Spigel,
J. West
11:28
CancerGRACE
2020 ASCO Update on 1L Advanced NSCLC: Is Nivo + Ipi + Limited Cours…
Feat.
H. Yu,
D. Spigel,
J. West
11:22
CancerGRACE
2020 ASCO Update on Advanced NSCLC: What Is the Role for Nivolumab/I…
Feat.
H. Yu,
D. Spigel,
J. West
09:02
CancerGRACE
2020 ASCO Update on MET/RET+ NSCLC: How Promising Are Capmatinib &am…
Feat.
H. Yu,
D. Spigel,
J. West
08:25
CancerGRACE
2020 ASCO Update on HER2+ NSCLC: Is There a Promising Clinical Activ…
Feat.
H. Yu,
D. Spigel,
J. West
12:16
CancerGRACE
2020 ASCO Update on EGFR+ NSCLC: Does Upfront SBRT to Sites at Diagn…
Feat.
H. Yu,
D. Spigel,
J. West
08:16
CancerGRACE
ASCO 2020 Updates on PD-L1 NSCLC: Is Tiragolumab+Atezo Beneficial fo…
Feat.
J. West,
H. Yu,
D. Spigel
05:32
GRACE
2020 Updates on SCLC: Have We Progressed in the Treatment of Relapse…
Feat.
T. Owonikoko
05:16
CancerGRACE
Liquid Biopsy in NSCLC: Does Adding Liquid Biopsy to Tissue Testing …
Feat.
C. Aggarwal
06:45
GRACE
SCLC Updates: What Are the Leading Immunotherapy Options?
Feat.
S. Liu
05:38
GRACE
Expert Discussion on mNSCLC: What Are the Leading Treatment Options …
Feat.
S. Liu
05:45
GRACE
2020 Update on Molecular Abnormalities in NSCLC: How Do MET Exon 14 …
Feat.
J. Bauml
05:56
CancerGRACE
The Role of IO for NSCLC Patients With Driver Mutations: What Data D…
Feat.
B. Levy
07:43
CancerGRACE
2020 Update on Targeted Therapies in NSCLC PD-L1 Expression: What Ar…
Feat.
M. Das
07:55
GRACE
Non-Small Cell Lung Cancer: Is Immunotherapy Safe for Frail Patients…
Feat.
M. Gubens
05:13
GRACE
Does Immunotherapy Have Activity in Malignant Pleural Mesothelioma?
Feat.
M. Das
06:15
CancerGRACE
Non-Small Cell Lung Cancer: How Does a Positive HER2 Mutation Affect…
Feat.
J. West,
J. Riess,
S. Padda
06:03
GRACE
ALK+ NSCLC With High PD-L1. What Is the First Line Treatment for Po…
Feat.
J. West,
J. Riess,
S. Padda
06:00
CancerGRACE
What Is the Importance of MET Amplification Level in EGFR+ NSCLC Wit…
Feat.
C. McCoach,
H. Wakelee,
J. West
03:45
GRACE
NSCLC EGFR Mutation Treated With Tagrisso: Progression While on Trea…
Feat.
C. McCoach,
H. Wakelee,
J. West
07:30
CancerGRACE
NSCLC EGFR Mutation and the FLAURA Trial: Is There a Difference in D…
Feat.
C. McCoach,
H. Wakelee,
J. West
08:20
GRACE
EGFR + NSCLC: Is There a Place for Chemo and the Inclusion of Immuno…
Feat.
J. West,
H. Wakelee,
C. McCoach
04:14
CancerGRACE
EGFR Mutation and High and High PD-L1 in NSCLC: What is the Role of …
Feat.
C. McCoach,
H. Wakelee,
J. West
05:18
CancerGRACE
Non-Small Cell Lung Cancer: What Are the Recommended Treatments for …
Feat.
C. McCoach,
H. Wakelee,
J. West
05:04
CancerGRACE
NSCLC With EGFR Mutation: What Are the Treatment Options with Oligop…
Feat.
C. McCoach,
H. Wakelee,
J. West
07:12
CancerGRACE
NSCLC With EGFR Mutation: Is There a Place for Chemotherapy and an E…
Feat.
C. McCoach,
H. Wakelee,
J. West
05:52
CancerGRACE
NSCLC With EGFR Uncommon Exon 20 Mutation: Suggested Treatments, Tar…
Feat.
C. McCoach,
H. Wakelee,
J. West
04:20
GRACE
The Challenges of Potential Pneumonitis Following Durvalumab in Stag…
Feat.
M. Gubens,
J. West,
M. Das
06:03
CancerGRACE
Would IO Be Beneficial for Stage 3 NSCLC Patient with PDL1-0 After S…
Feat.
M. Gubens,
J. West,
M. Das
08:02
CancerGRACE
Best Schedule for Durvalumab for Older Patient in Stage 3 NSCLC Afte…
Feat.
J. West,
M. Gubens,
M. Das
05:12
CancerGRACE
Unresectable NSCLC: What Is TMB and Does it Add Significant Benefit …
Feat.
M. Gubens,
J. West,
M. Das
08:50
GRACE
Does Checkmate 227's Suggestion of an IO Combination of Ipi + N…
Feat.
M. Gubens,
J. West,
M. Das
10:58
CancerGRACE
Should Molecular Tests Be Considered in Stage 3 NSCLC and Would Outc…
Feat.
M. Gubens,
J. West,
M. Das
09:22
CancerGRACE
Case of 60 y/o Woman with ALK Positive Metastatic NSCLC: Approach to…
Feat.
S. Padda,
J. Riess,
J. West
06:14
GRACE
Case of ALK Positive Patient with Asymptomatic Brain Metastases: Is …
Feat.
S. Padda,
J. Riess,
J. West
09:45
GRACE
Treatment for NSCLC Patient Who Developed Resistance to ALK Inhibito…
Feat.
S. Padda,
J. Riess,
J. West
11:11
GRACE
Is the Standard Treatment the Best Approach for Stage 3 Frail Patien…
Feat.
M. Gubens,
J. West,
M. Das
06:43
CancerGRACE
Should We Continue the ALK Inhibitor in NSCLC Patient with Brain Met…
Feat.
S. Padda,
J. Riess,
J. West
10:53
CancerGRACE
Is There a Role for Combination Therapies Like Chemo/Radio and IO fo…
Feat.
S. Padda,
J. Riess,
J. West
09:53
GRACE
Stage 3 NSCLC - Standard Concurrent Chemo + Radiation, Followed by I…
Feat.
M. Gubens,
J. West,
M. Das
11:27
CancerGRACE
Stage 3 NSCLC: Is the Standard Treatment of Chemo and Radiation Foll…
Feat.
M. Gubens,
J. West,
M. Das
11:26
CancerGRACE
Case Based Discussion on Stage 3 NSCLC: Should We Do Molecular Tests…
Feat.
M. Gubens,
J. West,
M. Das
05:24
GRACE
CancerGRACE's ASCO 2019 Update on Lung Cancer: How Promising is…
Feat.
J. West,
B. Levy,
C. Aggarwal
05:32
CancerGRACE
CancerGRACE's ASCO 2019 Update on Lung Cancer: Short Discussion…
Feat.
J. West,
B. Levy,
C. Aggarwal
06:02
CancerGRACE
CancerGRACE's ASCO 2019 Update on Lung Cancer: Circulating Tumo…
Feat.
J. West,
B. Levy,
C. Aggarwal
05:53
CancerGRACE
CancerGRACE's ASCO 2019 Update on Lung Cancer: Retrospective An…
Feat.
J. West,
B. Levy,
C. Aggarwal
03:55
CancerGRACE
CancerGRACE's ASCO 2019 Update on Stage IV NSCLC: New Targets -…
Feat.
J. West,
B. Levy,
C. Aggarwal
06:33
CancerGRACE
CancerGRACE's ASCO 2019 Highlights and New Approaches in Stage …
Feat.
J. West,
B. Levy,
C. Aggarwal
07:14
CancerGRACE
CancerGRACE's ASCO 2019 Highlights and New Approaches in Stage …
Feat.
J. West,
B. Levy,
C. Aggarwal
06:33
CancerGRACE
CancerGRACE's 2019 ASCO Highlights in Advanced NSCLC: What is t…
Feat.
J. West,
B. Levy,
C. Aggarwal
06:38
CancerGRACE
CancerGRACE's 2019 ASCO Highlights on Adjuvant Afatinib in Stag…
Feat.
J. West,
B. Levy,
C. Aggarwal
07:26
CancerGRACE
CancerGRACE's 2019 ASCO Highlights on Stage I NSCLC Adjuvant Ch…
Feat.
J. West,
B. Levy,
C. Aggarwal
21:24
GRACE
Is There a Role for IO in EGFR+ Metastatic Lung Cancer?
Feat.
H. Yu
47:56
CancerGRACE
Initial Treatment and Acquired Resistance in Advanced Lung Cancer &a…
Feat.
J. Bauml,
J. Sabari
21:58
CancerGRACE
Q&A on Targeted Therapies in Advanced Lung Cancer
Feat.
J. Bauml
19:19
GRACE
Introduction to Next Generation Sequencing in Metastatic Lung Cancer…
Feat.
J. Bauml
23:26
CancerGRACE
EGFR Initial Treatment and Acquired Resistance in Advanced NSCLC
Feat.
H. Yu
09:30
GRACE
Q&A on EGFR Initial Treatment and Acquired Resistance in Advance…
Feat.
H. Yu
07:53
CancerGRACE
Optimal First Line Treatment of EGFR+ Advanced NSCLC: First and Seco…
Feat.
J. West
18:32
CancerGRACE
Optimal First Line Treatment of EGFR+ Advanced NSCLC: Osimertinib vs…
Feat.
J. West
17:04
CancerGRACE
Optimal First Line Treatment of EGFR+ Advanced NSCLC: Dacomitinib, E…
Feat.
J. West
17:10
CancerGRACE
Targeted Therapies in Advanced Lung Cancer: What is the Role of Rebi…
Feat.
H. Borghaei
26:54
CancerGRACE
Discussion/Q&A on Targeted Therapies in Advanced Lung Cancer
Feat.
H. Borghaei
15:23
GRACE
Targeted Therapies in Metastatic NSCLC: Liquid Biopsies as a New Opt…
Feat.
C. Aggarwal
02:13
CancerGRACE
Immunotherapy in Stage lll NSCLC - The Pacific Trial and Imfinzi
Feat.
K. Kelly
01:54
CancerGRACE
Tumor Mutation Burden in Patients with Non-Squamous NSCLC: Current S…
Feat.
S. Patel
02:41
CancerGRACE
Evolving Standards for Molecular Testing in Advanced NSCLC
Feat.
S. Patel
02:05
CancerGRACE
Combinations of Immunotherapy Agents in Advanced NSCLC: Current Stat…
Feat.
S. Patel
02:17
GRACE
The Basics of Managing Immune-Mediated Side Effects in NSCLC
Feat.
S. Patel
03:50
CancerGRACE
What Should Patients With Rapid Progression in Advanced NSCLC Throug…
Feat.
J. West
04:46
GRACE
"Consolidation" Radiation After a Good Response to First L…
Feat.
J. West
06:57
CancerGRACE
Chemotherapy and Immunotherapy Combinations in Advanced Non-Squamous…
Feat.
J. West
05:39
CancerGRACE
Chemo Immuno Therapy Combinations in Advanced Squamous NSCLC
Feat.
J. West
07:13
CancerGRACE
Does Immunotherapy Work in Patients with Driver Mutations Like EGFR …
Feat.
J. West
04:09
CancerGRACE
EGFR TKI Gilotrif(Afatinib) in Metastatic Squamous NSCLC
Feat.
V. Velcheti
04:24
CancerGRACE
Lung Cancer Immunotherapy- Is There Anything Better than PDL1
Feat.
V. Velcheti
03:20
GRACE
MET as a Target in Advanced NSCLC
Feat.
V. Velcheti
04:33
CancerGRACE
The Changing Landscape of 1L Treatment of ALK-Positive Advanced NSCL…
Feat.
A. Shaw
06:02
GRACE
Patterns of Resistance in ALK Positive NSCLC
Feat.
A. Shaw
05:04
GRACE
Controlling Brain Metastases in Patients with Molecular Driven Advan…
Feat.
A. Shaw
02:14
CancerGRACE
Immunotherapy for Previously Treated Patients with NSCLC
Feat.
K. Reckamp
04:50
CancerGRACE
New Options in Acquired Resistance for ALK+ Metastatic Non-small Cel…
Feat.
N. Pennell
03:45
CancerGRACE
The Role for Immunotherapy in Patients with a Driver Mutation Lung C…
Feat.
N. Pennell
03:35
CancerGRACE
Liquid Biopsies for Broad Genomic Testing in Lung Cancer
Feat.
N. Pennell
03:53
CancerGRACE
Liquid Biopsies for EGFR T790M Advanced NSCLC
Feat.
N. Pennell
02:45
CancerGRACE
The Role of Angiogenesis in Previously Treated NSCLC
Feat.
K. Reckamp
09:07
CancerGRACE
Advanced Non Squamous NSCLC, High PD-L1, No Mutation - Optimal 1st L…
Feat.
J. West,
Z. Piotrowska,
T. Owonikoko
12:59
CancerGRACE
Advanced Non Squamous NSCLC, Low PD-L1, No Mutation - Best Systemic …
Feat.
J. West,
Z. Piotrowska,
T. Owonikoko
11:09
CancerGRACE
Case Based Panel Discussion - Fit Patient Adv Squamous NSCLC Low Tum…
Feat.
J. West,
Z. Piotrowska,
T. Owonikoko
08:18
GRACE
Lung Cancer Case Based Panel Discussion - EGFR and High PDL-1, Choos…
Feat.
J. West,
Z. Piotrowska,
T. Owonikoko
09:21
CancerGRACE
Case Based Panel Discussions - Metastatic Squamous NSCLC Low Tumor P…
Feat.
J. West,
Z. Piotrowska,
T. Owonikoko
08:17
CancerGRACE
Rapid Progression Lung Adenocarcinoma High PD-L1 - How Do You Treat?…
Feat.
J. West,
Z. Piotrowska,
T. Owonikoko
11:15
GRACE
ASCO 2018 - Keynote 042 - Keytruda as a Single Agent Compared to Dou…
Feat.
K. Kelly,
J. West,
S. Patel
12:26
CancerGRACE
ASCO 2018 - Potential Showdown of Two Positive Trials? Keynote 407 a…
Feat.
K. Kelly,
J. West,
S. Patel
11:29
CancerGRACE
ASCO 2018 Keynote189 - Cisplatin or Carboplatin with Alimta & Ke…
Feat.
K. Kelly,
J. West,
S. Patel
09:40
CancerGRACE
ASCO 2018 - Checkmate 227 - Combinations of Nivolumab and Ipilimumab…
Feat.
K. Kelly,
J. West,
S. Patel
07:35
CancerGRACE
ASCO 2018 - Will Taking Mod to High Dose Steroids Affect Lung Cancer…
Feat.
K. Kelly,
J. West,
S. Patel
09:11
CancerGRACE
ASCO 2018 - Tarceva or Tarceva with Avastin as 1st Line for EGFR Pos…
Feat.
K. Kelly,
J. West,
S. Patel
06:27
CancerGRACE
ASCO 2018 - Tarceva Combined with Carboplatin & Alimta - Given U…
Feat.
K. Kelly,
J. West,
S. Patel
02:52
CancerGRACE
ASCO 2018 - Combining Metformin with Standard EGFR Therapy - Is the …
Feat.
K. Kelly,
J. West,
S. Patel
03:34
GRACE
ASCO 2018 - Keynote 158 - Keytruda in Previously Treated, Now Relaps…
Feat.
K. Kelly,
J. West,
S. Patel
04:26
GRACE
ASCO 2018 - Dream Study - Chemo with Imfinzi (durvalumab) for Mesoth…
Feat.
K. Kelly,
J. West,
S. Patel
25:01
CancerGRACE
OncTalk 2018 - Newer Technologies in Radiation - Local Therapies for…
Feat.
V. Mehta
21:07
CancerGRACE
OncTalk 2018 - Novel Indications for Local Therapy in Adv NSCLC - Lo…
Feat.
P. Iyengar
19:01
GRACE
NSCLC - Local Therapies for Metastatic LC
Feat.
E. Vallieres
27:13
CancerGRACE
OncTalk 2018 - Systemic Therapies for Advanced NSCLC - Local Therapi…
Feat.
J. West
45:31
CancerGRACE
OncTalk 2018 - Panel Discussion and Q&A - Local Therapies for Me…
Feat.
E. Vallieres,
J. West,
V. Mehta,
P. Iyengar
